The NCI RAS Program
- The Problem
- A Collaborative Solution
- RAS Projects at NCI/FNL
- RAS Laboratory Groups
- RAS Program Oversight
- RAS Spokes
- Help Advance the Research
- More About the RAS Program
The NCI RAS Program
NCI established the RAS Program to explore innovative ways to attack the proteins encoded by mutant forms of the RAS genes or other vulnerabilities as a way to treat key types of cancer, including pancreatic, lung, and colorectal cancers. We encourage you to collaborate with RAS experts, find and use reagents and tools, and help us solve the RAS challenge.
The NCI RAS Program At-a-Glance
- NCI’s goal is to attack RAS-driven cancers through an integrated, collaborative program that hopefully will result in effective new therapies for patients with tumors that have RAS mutations.
- The RAS Program is based at the NCI Frederick National Laboratory for Cancer Research (FNL)in Frederick, MD.
- Existing FNL funding has been redirected to support the RAS Program.
- Dr. Frank McCormick leads the program’s scientific efforts.
RAS Central
Post comments, ask questions, and share information with RAS experts on the RAS Central page. Join the scientific discussion!
What’s Happening Now
2014 UCSF Seminar Videos Posted
Ten presentations from the symposium "Targeting RAS Now for Future Cancer Therapy," held at the University of California, San Francisco, June 19th and 20th, 2014, are now available.
New Message from Dr. Frank McCormick
Dr. Frank McCormick discusses his vision for the NCI RAS Program and encourages collaboration among the 1,500 labs worldwide that work on the RAS pathways every day.
New Commentary from Dr. Channing Der
Dr. Der asks why the four RAS proteins are implicated in different human cancers in his new, in-depth commentary.RAS Pathways & Reagents
Obtain unique and powerful RAS and RAS pathway reagents developed at FNL.
- RAS Entry Clone Collection 1
- 15 RAS pathway genes
- Open and closed formats
- Plasmid DNA and glycerol stocks of E. coli DH10B harboring each plasmid
- KRAS Entry Clone Collection 1
- Wild-type KRAS and 10 point mutations
- Open and closed formats
- Plasmid DNA and glycerol stocks of E. coli DH10B harboring each plasmid
No hay comentarios:
Publicar un comentario